Oncologie

, Volume 12, Issue 10, pp 584–592 | Cite as

Vers un traitement personnalisé du cancer colorectal: facteurs pronostiques et prédictifs

Oncologie
  • 79 Downloads

Résumé

Le cancer colorectal (CCR) reste un problème majeur de santé publique malgré l’avènement de plusieurs chimiothérapies et thérapies ciblées. L’identification de facteurs pronostiques, mais aussi de facteurs prédictifs de la réponse à ces différents traitements et de leur toxicité est devenue un enjeu majeur afin d’optimiser et de personnaliser le traitement du CCR. Si peu de facteurs moléculaires sont validés dans le domaine du pronostic des CCR où la classification TNM reste le principal paramètre utilisé en pratique clinique, il n’en est pas de même des facteurs moléculaires prédictifs. Plusieurs d’entre eux sont désormais validés pour la prédiction de la réponse à certains traitements (mutations de KRAS et anticorps anti-EGFR) ou à leur toxicité (dihydropyrimidine déshydrogénase [DPD] et 5-fluorouracile [5-FU], polymorphismes de l’UDP-glucuronosyltransférase 1A1 [UGT 1A1] et irinotécan) et ouvrent la voie d’un traitement personnalisé du CCR.

Mots clés

Cancer colorectal Pronostic Chimiothérapie Anticorps anti-EGFR KRAS 

Toward a personalized treatment of colorectal cancer: prognostic and predictive factors

Abstract

Colorectal cancer (CRC) remains a major public health problem despite the advent of several conventional chemotherapies and targeted therapies. The identification of prognostic factors, and also factors that can predict response to different treatments and their toxicity, has become amajor issue in order to optimize and personalize treatment of CRC patients. Although few molecular factors are validated in the field of CRC prognosis where the TNM classification is the main parameter used in clinical practice, the fact is not true for molecular predictive factors. Several of them are now validated for predicting response to certain treatments (KRAS mutations and anti-EGFR antibodies) and their toxicity (dihydropyrimidine déshydrogenase [DPD] for 5-fluorouracil [5-FU], UDP-glucuronosyltransferase 1A1 [UGT 1A1] polymorphism for irinotecan) and open up the way of personalized treatment of CRC.

Keywords

Colorectal cancer Prognostic Chemotherapy Anti-EGFR antibodies KRAS 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Références

  1. 1.
    Amado RG, Wolf M, Peeters M, et al. (2008) Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. J Clin Oncol 26: 1626–1634CrossRefPubMedGoogle Scholar
  2. 2.
    Andre T, Boni C, Mounedji-Boudiaf L, et al. (2004) Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer. N Engl J Med 350: 2343–2351CrossRefPubMedGoogle Scholar
  3. 3.
    Barnetson RA, Tenesa A, Farrington SM, et al. (2006) Identification and survival of carriers of mutations in DNA mismatch-repair genes in colon cancer. N Engl J Med 354: 2751–2763CrossRefPubMedGoogle Scholar
  4. 4.
    Bokemeyer C, Bondarenko I, Makhson A, et al. (2009) Fluorouracil, leucovorin, and oxaliplatin with and without cetuximab in the first-line treatment of metastatic colorectal cancer. J Clin Oncol 27:663–671CrossRefPubMedGoogle Scholar
  5. 5.
    Boland CR, Goel A Microsatellite instability in colorectal cancer. Gastroenterology 138:2073–2087 e3Google Scholar
  6. 6.
    Cunningham D, Humblet Y, Siena S, et al. (2004) Cetuximab monotherapy and cetuximab plus irinotecan in irinotecanrefractory metastatic colorectal cancer. N Engl J Med 351: 337–345CrossRefPubMedGoogle Scholar
  7. 7.
    Di Fiore F, Michel P (2009) [Prognostic role of KRAS mutation in colorectal cancer]. Bull Cancer 96: S23–S30PubMedGoogle Scholar
  8. 8.
    Diep CB, Thorstensen L, Meling GI, et al. (2003) Genetic tumor markers with prognostic impact in Dukes’ stages B and C colorectal cancer patients. J Clin Oncol 21: 820–829CrossRefPubMedGoogle Scholar
  9. 9.
    Duffy MJ, van Dalen A, Haglund C, et al. (2007) Tumour markers in colorectal cancer: European Group on Tumour Markers (EGTM) guidelines for clinical use. Eur J Cancer 43: 1348–1360CrossRefPubMedGoogle Scholar
  10. 10.
    Etienne MC, Chazal M, Laurent-Puig P, et al. (2002) Prognostic value of tumoral thymidylate synthase and p53 in metastatic colorectal cancer patients receiving fluorouracil-based chemotherapy: phenotypic and genotypic analyses. J Clin Oncol 20: 2832–2843CrossRefPubMedGoogle Scholar
  11. 11.
    Gunderson LL, Jessup JM, Sargent DJ, et al. (2010) Revised TN categorization for colon cancer based on national survival outcomes data. J Clin Oncol 28: 264–271CrossRefPubMedGoogle Scholar
  12. 12.
    Gunderson LL, Jessup JM, Sargent DJ, et al. (2010) Revised tumor and node categorization for rectal cancer based on surveillance, epidemiology, and end results and rectal pooled analysis outcomes. J Clin Oncol 28: 256–263CrossRefPubMedGoogle Scholar
  13. 13.
  14. 14.
  15. 15.
    Iacopetta B, Grieu F, Joseph D, et al. (2001) A polymorphism in the enhancer region of the thymidylate synthase promoter influences the survival of colorectal cancer patients treated with 5-fluorouracil. Br J Cancer 85: 827–830CrossRefPubMedGoogle Scholar
  16. 16.
    Jen J, Kim H, Piantadosi S, et al. (1994) Allelic loss of chromosome 18q and prognosis in colorectal cancer. N Engl J Med 331: 213–221CrossRefPubMedGoogle Scholar
  17. 17.
    Jonker D, Karapetis C, Moore M, et al. (2007) Randomized phase III trial of cetuximab monotherapy plus best supportive care (BSC) versus BSC alone in patients with pretreated metastatic epidermal growth factor receptor (EGFR)-positive colorectal carcinoma: a trial of the National Cancer Institute of Canada Clinical Trials Group (NCIC CTG) and the Australasian Gastro-Intestinal Trials Group (AGITG). American Association for Cancer Research Annual meeting late breaking abstract 1Google Scholar
  18. 18.
    Karapetis CS, Khambata-Ford S, Jonker DJ, et al. (2008) KRAS mutations and benefit from cetuximab in advanced colorectal cancer. N Engl J Med 359: 1757–1765CrossRefPubMedGoogle Scholar
  19. 19.
    Kim GP, Colangelo LH, Wieand HS, et al. (2007) Prognostic and predictive roles of high-degree microsatellite instability in colon cancer: a National Cancer Institute-National Surgical Adjuvant Breast and Bowel Project Collaborative Study. J Clin Oncol 25: 767–772CrossRefPubMedGoogle Scholar
  20. 20.
    Lanza G, Gafa R, Santini A, et al. (1998) Prognostic significance of DNA ploidy in patients with stage II and stage III colon carcinoma: a prospective flow cytometric study. Cancer 82: 49–59CrossRefPubMedGoogle Scholar
  21. 21.
    Lanza G, Matteuzzi M, Gafa R, et al. (1998) Chromosome 18q allelic loss and prognosis in stage II and III colon cancer. Int J Cancer 79: 390–395CrossRefPubMedGoogle Scholar
  22. 22.
    Laurent-Puig P, Lievre A, Ducreux M, et al. (2008) [The biological point of view on pharmacogenetics of anticancer agents in colorectal cancer]. Bull Cancer 95: 935–942PubMedGoogle Scholar
  23. 23.
    Le Morvan V, Smith D, Laurand A, et al. (2007) Determination of ERCC2 Lys751Gln and GSTP1 Ile105Val gene polymorphisms in colorectal cancer patients: relationships with treatment outcome. Pharmacogenomics 8: 1693–1703CrossRefPubMedGoogle Scholar
  24. 24.
    Lecomte T, Landi B, Beaune P, et al. (2006) Glutathion S-transferases P1 polymorphism (Ile105Val) predicts cumulative neuropathy in patients receiving oxaliplatin-based chemotherapy. Clin Cancer Res 12: 3050–3056CrossRefPubMedGoogle Scholar
  25. 25.
    Lievre A, Bachet JB, Boige V, et al. (2008) KRAS mutations as an independent prognostic factor in patients with advanced colorectal cancer treated with cetuximab. J Clin Oncol 26: 374–379CrossRefPubMedGoogle Scholar
  26. 26.
    Lievre A, Blons H, Laurent-Puig P Oncogenic mutations as predictive factors in colorectal cancer. Oncogene 29: 3033–30343Google Scholar
  27. 27.
    Locker GY, Hamilton S, Harris J, et al. (2006) ASCO 2006 update of recommendations for the use of tumor markers in gastrointestinal cancer. J Clin Oncol 24: 5313–5327CrossRefPubMedGoogle Scholar
  28. 28.
    McLeod HL, Sargent DJ, Marsh S, et al. (2010) Pharmacogenetic predictors of adverse events and response to chemotherapy in metastatic colorectal cancer: results from North American Gastrointestinal Intergroup Trial N9741. J Clin Oncol 28: 3227–3233CrossRefPubMedGoogle Scholar
  29. 29.
    Morel A, Boisdron-Celle M, Fey L, et al. (2006) Clinical relevance of different dihydropyrimidine dehydrogenase gene single nucleotide polymorphisms on 5-fluorouracil tolerance. Mol Cancer Ther 5: 2895–2904CrossRefPubMedGoogle Scholar
  30. 30.
    O’Dwyer PJ, Catalano RB (2006) Uridine diphosphate glucuronosyltransferase (UGT) 1A1 and irinotecan: practical pharmacogenomics arrives in cancer therapy. J Clin Oncol 24: 4534–4538CrossRefPubMedGoogle Scholar
  31. 31.
    Ogino S, Nosho K, Irahara N, et al. (2009) Prognostic significance and molecular associations of 18q loss of heterozygosity: a cohort study of microsatellite stable colorectal cancers. J Clin Oncol 27: 4591–4598CrossRefPubMedGoogle Scholar
  32. 32.
    Ogunbiyi OA, Goodfellow PJ, Herfarth K, et al. (1998) Confirmation that chromosome 18q allelic loss in colon cancer is a prognostic indicator. J Clin Oncol 16: 427–433PubMedGoogle Scholar
  33. 33.
    Parc Y, Gueroult S, Mourra N, et al. (2004) Prognostic significance of microsatellite instability determined by immunohistochemical staining of MSH2 and MLH1 in sporadic T3N0M0 colon cancer. Gut 53: 371–375CrossRefPubMedGoogle Scholar
  34. 34.
    Popat S, Houlston RS (2005) A systematic review and meta-analysis of the relationship between chromosome 18q genotype, DCC status and colorectal cancer prognosis. Eur J Cancer 41: 2060–2070CrossRefPubMedGoogle Scholar
  35. 35.
    Popat S, Hubner R, Houlston RS (2005) Systematic review of microsatellite instability and colorectal cancer prognosis. J Clin Oncol 23: 609–618CrossRefPubMedGoogle Scholar
  36. 36.
    Pullarkat ST, Stoehlmacher J, Ghaderi V, et al. (2001) Thymidylate synthase gene polymorphism determines response and toxicity of 5-FU chemotherapy. Pharmacogenomics J 1:65–70PubMedGoogle Scholar
  37. 37.
    Sanoff HK, McLeod HL (2008) Predictive factors for response and toxicity in chemotherapy: pharmacogenomics. Semin Colon Rectal Surg 19: 226–230CrossRefPubMedGoogle Scholar
  38. 38.
    Sargent DJ, Marsoni S, Monges G, et al. (2010) Defective mismatch repair as a predictive marker for lack of efficacy of fluorouracil-based adjuvant therapy in colon cancer. J Clin Oncol 28: 3219–3226CrossRefPubMedGoogle Scholar
  39. 39.
    Shirota Y, Stoehlmacher J, Brabender J, et al. (2001) ERCC1 and thymidylate synthase mRNA levels predict survival for colorectal cancer patients receiving combination oxaliplatin and fluorouracil chemotherapy. J Clin Oncol 19: 4298–4304PubMedGoogle Scholar
  40. 40.
    Sobrero AF, Maurel J, Fehrenbacher L, et al. (2008) EPIC: phase III trial of cetuximab plus irinotecan after fluoropyrimidine and oxaliplatin failure in patients with metastatic colorectal cancer. J Clin Oncol 26: 2311–2319CrossRefPubMedGoogle Scholar
  41. 41.
    Stoehlmacher J, Park DJ, Zhang W, et al. (2002) Association between glutathione S-transferase P1, T1, and M1 genetic polymorphism and survival of patients with metastatic colorectal cancer. J Natl Cancer Inst 94: 936–942PubMedGoogle Scholar
  42. 42.
    Van Cutsem E, Kohne CH, Hitre E, et al. (2009) Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. N Engl J Med 360: 1408–1417CrossRefPubMedGoogle Scholar
  43. 43.
    Van Cutsem E, Peeters M, Siena S, et al. (2007) Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer. J Clin Oncol 25: 1658–1664CrossRefPubMedGoogle Scholar
  44. 44.
    Viguier J, Boige V, Miquel C, et al. (2005) ERCC1 codon 118 polymorphism is a predictive factor for the tumor response to oxaliplatin/5-fluorouracil combination chemotherapy in patients with advanced colorectal cancer. Clin Cancer Res 11: 6212–6217CrossRefPubMedGoogle Scholar
  45. 45.
    Walther A, Houlston R, Tomlinson I (2008) Association between chromosomal instability and prognosis in colorectal cancer: a meta-analysis. Gut 57: 941–950CrossRefPubMedGoogle Scholar
  46. 46.
    Yen JL, McLeod HL (2007) Should DPD analysis be required prior to prescribing fluoropyrimidines? Eur J Cancer 43:1011–1016CrossRefPubMedGoogle Scholar
  47. 47.
    Zhou W, Goodman SN, Galizia G, et al. (2002) Counting alleles to predict recurrence of early-stage colorectal cancers. Lancet 359: 219–225CrossRefPubMedGoogle Scholar
  48. 48.
    Zlobec I, Lugli A (2008) Prognostic and predictive factors in colorectal cancer. J Clin Pathol 61: 561–569PubMedGoogle Scholar

Copyright information

© Springer Verlag France 2010

Authors and Affiliations

  1. 1.Service d’hépatogastroentérologie et oncologie digestivehôpital Ambroise-Paré, AP-HPBoulogne-BillancourtFrance
  2. 2.Université Versailles Saint-Quentin-en-YvelinesVersaillesFrance

Personalised recommendations